Un­pack­ing FDA’s lat­est Alzheimer’s OK; A look at all drugs ap­proved in 2022; Mod­er­na’s deal spree; Pfiz­er re­vamps ear­ly re­search; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Sure, deals are what it’s all about at JPM. But I’ll be walk­ing around San Fran­cis­co with a spe­cial ear to what peo­ple say about lecanemab. Hit me with thoughts on the land­mark Alzheimer’s ap­proval — or any oth­er pre­dic­tions for the year to come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER